SCHEMBL4827032

SCHEMBL4827032

CN1CCn2c(nc(C(=O)NCc3ccc(F)cc3-n3cncn3)c(O)c2=O)C12CCCC2

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.37
KCNH2 Q12809 1/20 0.36
CALCA P06881 4/20 0.33
HCRTR1 O43613 1/20 0.31
LIPG Q9Y5X9 2/20 0.31
F2 P00734 2/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
KCNE1 P15382 1/20 0.30
CCR1 P32246 1/20 0.30
KCNQ1 P51787 1/20 0.30
CYP3A4 P08684 2/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2C19 P33261 1/20 0.30
MET P08581 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4832814 0.99 CYP2C9 (0.37) CYP2C9KCNH2CALCAHCRTR1LIPG
SCHEMBL4832837 0.98 CYP2C9 (0.37) CYP2C9KCNH2CALCAHCRTR1LIPG
SCHEMBL1378995 0.90 CYP2C9 (0.42) CYP2C9KCNH2CALCAHCRTR1LIPG
SCHEMBL1379630 0.89 CYP2C9 (0.41) CYP2C9KCNH2CALCAHCRTR1F2
SCHEMBL3841171 0.88 CYP2C9 (0.37) CYP2C9KCNH2CALCAHCRTR1F2
SCHEMBL3836245 0.88 CYP2C9 (0.39) CYP2C9KCNH2CALCAHCRTR1F2
SCHEMBL1381752 0.88 CYP2C9 (0.38) CYP2C9KCNH2CALCAHCRTR1F2
SCHEMBL3840248 0.87 CYP2C9 (0.39) CYP2C9KCNH2CALCAHCRTR1F2
SCHEMBL4822949 0.86 CYP2C9 (0.37) CYP2C9KCNH2CALCALIPGKCNE1
SCHEMBL3838371 0.86 CYP2C9 (0.35) CYP2C9KCNH2CALCAHCRTR1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7419969-B2 HIV integrase inhibitors: cyclic pyrimidinone compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2008-09-02 US claimed
US-20060106007-A1 HIV integrase inhibitors: cyclic pyrimidinone compounds ROBERT BOSCH GMBH (DE) 2006-05-18 US claimed
US-7419969-B2 HIV integrase inhibitors: cyclic pyrimidinone compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2008-09-02 US disclosed
US-7419969-B2 HIV integrase inhibitors: cyclic pyrimidinone compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2008-09-02 US disclosed
US-7419969-B2 HIV integrase inhibitors: cyclic pyrimidinone compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2008-09-02 US disclosed
WO-2007058646-A1 HIV INTEGRASE INHIBITORS: CYCLIC PYRIMIDINONE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-24 WO disclosed
US-20060106007-A1 HIV integrase inhibitors: cyclic pyrimidinone compounds ROBERT BOSCH GMBH (DE) 2006-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106007-A1 HIV integrase inhibitors: cyclic pyrimidinone compounds TYMP, TYMS, SAMHD1 CYP2C9 1079/4885KCNH2 3435/4885CALCA 2904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.